Development of [ 99m Tc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Christian Lis und 12 weiteren Autor:innen. Beteiligte Einrichtung: ABX Advanced Biochemical Compounds GmbH, Heinrich-Gläser-Straße 10-14, 01454 Radeberg, Germany. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Organotechnetium Compounds, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Regional Development Fund, Landtag of Saxony.
Abstract (Originalsprache)
A current global limitation to the timely and equitable patient access to PSMA-based therapies for prostate cancer (PCa) is the insufficient PET capacity for pretreatment imaging. However, the extensive global availability of SPECT cameras renders this imaging technology as an attractive alternative. The lack of regulatory approved PSMA radioligands for SPECT imaging of PCa prompted us to design new 99mTc-labeled radioligands with a fast pharmacokinetic profile by harnessing proven complexation of the [99mTc][TcO]3+ core by a bis(aminoethanethiol) chelator. Six 99mTc-labeled PSMA radioligands were synthesized and biologically characterized in cell-based assays and by SPECT imaging in LNCaP tumor-bearing mice. From this series, [99mTc]TcO-5 ([99mTc]TcO-ABX474, Kd(PSMA) = 6.1 ± 1.7 nM) displayed the most advantageous properties for SPECT imaging of PCa: high and fast tumor uptake accompanied by rapid clearance from nontarget tissues, leading to faster pharmacokinetics than observed for the reference [99mTc]Tc-PSMA-I&S. Furthermore, [99mTc]TcO-5 performed similar to the established PSMA-PET radioligand [68Ga]Ga-PSMA-11.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ABX Advanced Biochemical Compounds GmbH, Heinrich-Gläser-Straße 10-14, 01454 Radeberg, Germany.
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Bautzner Landstraße 400, 01328 Dresden, Germany.
- School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Mommsenstraße 4, 01069 Dresden, Germany.
- German Cancer Consortium (DKTK), Partner Site Dresden, 01307 Dresden, Germany.
- National Center for Tumor Diseases (NCT), Partner Site Dresden, University Cancer Center (UCC), 01307 Dresden, Germany.
- University Medical Center Schleswig-Holstein, Ratzeburger Allee 160, 23562 Lübeck, Germany.
ORCID-Profile: Friedrich-Alexander Ludwig, Wiebke Sihver, Daniel Gündel, Jens Pietzsch, Alexander Hoepping
Förderung
- European Regional Development Fund
- Landtag of Saxony
Zitieren
APA
Lis, C., Ludwig, F. A., Fischer, S., Ullrich, M., Lankau, H. J., Sihver, W., Gündel, D., Joseph, D., Meyer, C., Kopka, K., Pietzsch, J., Brust, P., & Hoepping, A. (2025). Development of [ 99m Tc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02767
Vancouver
Lis C, Ludwig FA, Fischer S, Ullrich M, Lankau HJ, Sihver W, et al. Development of [ 99m Tc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02767
BibTeX
@article{Lis2025,
author = {Lis, Christian and Ludwig, Friedrich-Alexander and Fischer, Steffen and Ullrich, Martin and Lankau, Hans-Joachim and Sihver, Wiebke and Gündel, Daniel and Joseph, Desna and Meyer, Christoph and Kopka, Klaus and Pietzsch, Jens and Brust, Peter and Hoepping, Alexander},
title = {Development of [ 99m Tc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02767}
}
EUVIMED